Co-Diagnostics outlines clinical trial timeline and targets mid-2026 commercialization for PCR platform
Source: SeekingAlpha
2025-08-14 19:42:57 ET
More on Co-Diagnostics
- Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript
- Seeking Alpha’s Quant Rating on Co-Diagnostics
- Historical earnings data for Co-Diagnostics
- Financial information for Co-Diagnostics
Read the full article on Seeking Alpha
For further details see:
Co-Diagnostics outlines clinical trial timeline and targets mid-2026 commercialization for PCR platform
Co-Diagnostics Inc.
NASDAQ: CODX
CODX Trading
46.03% G/L:
$2.015 Last:
98,317,390 Volume:
$1.95 Open:
CODX Latest News
May 19, 2026 10:54:00 pm
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesMay 19, 2026 09:00:00 am
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak AlertCODX Stock Data
$4,902,373
1,981,899
N/A
2
2252057%
Medical Equipment & Supplies
Healthcare
US
Salt Lake City
